Is sitagliptin effective for the treatment of COVID-19?

MEMİŞ, Hasan; Çakır, Ahmet; Durmuş, Mefküre; Gök, Selim; Bahçecíoğlu, Ömer Faruk

doi:10.1136/ejhpharm-2021-002702

Cited by 4 publications

(4 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Resultsmentioning

confidence: 99%

“…These models found that the SARS-CoV-2 interacts with DPP4 enzyme as a co-receptor, yet, this interaction is less strong than that of SARS-Cov-2 with ACE2. 25 Therefore, two articles suggested that DPP4 may be a co-receptor for SARS-CoV-2 viral entry 24,26 and there is a possible role for sitagliptin to prevent the binding of spike protein and thus viral hijacking and virulence, 20,23,[27][28][29] thereby preventing the injury to the lung and multiorgan failure. 23 However, Strollo and Pozzilli raised the issue of the low ability of sitagliptin to block SARS-CoV-2 viral entry than linagliptin and alogliptin because it acts as a substrate competitive inhibitor of DPP4 and has a shorter distance (17 amino acids) from one of the predicted binding sites (V341) of SARS-CoV-2.…”

Section: Effectiveness Of Sitagliptinmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and Safety of Sitagliptin in the Treatment of COVID-19

Mikhael

Ong

Ghadzi

2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

Background: Coronavirus disease 2019 (COVID-19) is associated with a high risk of mortality especially among diabetes mellitus (DM) patients. Effective treatments against COVID-19 can complement the vaccination effort worldwide. Many review articles studied the effects of the dipeptidyl peptidase 4 (DPP-4) inhibitors among COVID-19 patients and found conflicting results. This heterogeneity may be due to different systemic pleiotropic effects of different DPP-4 inhibitors. Sitagliptin appears to be one of the good DPP-4 inhibitors that have antiinflammatory and antithrombotic effect. Therefore, this review assessed the benefits and safety of sitagliptin in the treatment of COVID-19. Methods: A detailed literature review using the electronic databases of Pubmed and Google Scholar was conducted during July and August 2021 to find out studies that published in English language and discussed the role of sitagliptin for COVID-19 patients. Results: 14 articles were eligible and thus included in this narrative review. Nine of these articles agreed to the benefit of sitagliptin in the treatment of COVID-19, while 3 studies considered sitagliptin as non useful or even risky, and one study was neutral in its conclusion towards the usage of sitagliptin in COVID-19. Only one study focused on the safety of sitagliptin and found that it is safe. Conclusion: Sitagliptin has anti-inflammatory, antifibrotic and antiapoptotic properties; such effects may be beneficial in reducing risks of COVID-19. Sitagliptin has good safety and fair benefits to reduce mortality among DM patients with COVID-19. Further randomized clinical trials are needed to confirm these benefits especially among patients without DM.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Effectiveness Of Sitagliptinmentioning

confidence: 99%

Efficacy and Safety of Sitagliptin in the Treatment of COVID-19

Mikhael

Ong

Ghadzi

2022

Journal of Pharmacy Practice

View full text Add to dashboard Cite

show abstract

“…DPP4 is not a possible receptor for SARS-COV-2 entry [ 2 ]. However, the prolonged and excessive cytokine responses that are noted in COVID-19 patients can be decreased by Sitagliptin (SIT) [ [3] , [4] , [5] ]. SIT is anti-diabetic drug used to decrease incertins, which by its turn increase insulin re-lease leading to decreasing blood sugar [ 6 ].…”

Section: Introductionmentioning

confidence: 99%

Molecular docking studies of HIV TAT and sitagliptin nano-formula as potential therapeutic targeting SARS-CoV2 protease

Asfour

Alhakamy

Eljaaly

et al. 2021

Journal of the Indian Chemical Society

View full text Add to dashboard Cite

“…risk of acute symptoms is comparable to that of individuals without diabetes (10). The primary treatment for T2DM involves antidiabetic medications such as metformin and gliclazide, which improve insulin sensitivity, suppress gluconeogenesis, and enhance glucose absorption in tissues (11).…”

mentioning

confidence: 99%

Frequency of Mortality and Adverse Outcomes of COVID-19 in Hospitalized Type 2 Diabetics with a History of Sitagliptin or Metformin Use

Raji,

Rashidi,

Moradi

et al. 2024

Jundishapur J Chronic Dis Care

View full text Add to dashboard Cite

Background: The relationship between various blood glucose-lowering treatments for type 2 diabetes mellitus (T2DM) and the mortality and complication rates of COVID-19 infection holds significant relevance. Objectives: This retrospective study aimed to investigate the clinical progression of COVID-19 in T2DM patients previously treated with sitagliptin, metformin, or a combination of both. Methods: The study reviewed the medical records of T2DM patients with COVID-19 who had received treatment with sitagliptin, metformin, or both. Participants were selected from those admitted to Naft Hospital in Ahvaz, Iran, from March 2020 to March 2022. Data on mortality and adverse outcomes related to COVID-19 were gathered from the medical records. Results: The study included 529 diabetic patients treated with metformin (n = 197), sitagliptin (n = 231), or both (n = 101) for a minimum of three months. The overall mortality rate among diabetic patients was 15.1%, with the metformin group showing the highest mortality rate at 28.9% (P < 0.0001). Significant differences were observed among the three treatment groups in terms of the frequency of acute respiratory failure (P < 0.0001), stroke (P = 0.002), pulmonary embolism (P < 0.0001), and the necessity for ICU admission (P < 0.0001). Nonetheless, the incidence of myocardial infarction did not significantly differ between the groups. Conclusions: The findings suggest that sitagliptin use for blood sugar control in T2DM patients may help reduce adverse outcomes and the risk of death due to COVID-19. Mortality and morbidity rates were found to be higher in patients treated with metformin compared to those in the other groups.

show abstract

Is sitagliptin effective for the treatment of COVID-19?

Cited by 4 publications

References 5 publications

Efficacy and Safety of Sitagliptin in the Treatment of COVID-19

Efficacy and Safety of Sitagliptin in the Treatment of COVID-19

Molecular docking studies of HIV TAT and sitagliptin nano-formula as potential therapeutic targeting SARS-CoV2 protease

Frequency of Mortality and Adverse Outcomes of COVID-19 in Hospitalized Type 2 Diabetics with a History of Sitagliptin or Metformin Use

Contact Info

Product

Resources

About